108 terminated. 108 Phase 2, 20 Phase 3, 13 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 108 | Terminated 108 |
| Phase 3 | 20 | Terminated 20 |
| Phase 1 | 13 | Terminated 13 |
Follow Inflammation: new trials by email Literature Review of Inflammation trials Research Report on Inflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA Active tcVNS, Sham tcVNS - Juvenile Idiopathic Arthritis (JIA) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 18 | 2023-06-27 | 2025-11-25 |
| Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant Xylitol, Placebo - Allogeneic Stem Cell Transplantation | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 256 | 2023-04-04 | 2026-11-02 |
| An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease XPro1595 - Alzheimer Disease, Dementia | Phase 2 | Terminated | Inmune Bio, Inc. | 11 | 2023-02-21 | 2026-02-27 |
| Beta-glucan and Fatigue in HSCT Survivors Beta-glucan, Placebo - Autologous Haemopoietic Stem Cell Transplant | Phase 1 / Phase 2 | Terminated | University of Florida | 3 | 2023-02-10 | 2023-10-24 |
| Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1 Methadone, Buprenorphine/naloxone, XR-Naltrexone - Opioid-use Disorder, HIV-1-infection | Phase 2 | Terminated | University of Pennsylvania | 78 | 2023-01-30 | 2026-04-07 |
| Colchicine in HFpEF Colchicine, Placebo - Heart Failure, Inflammation | Phase 2 | Terminated | Montreal Heart Institute | 14 | 2022-06-17 | 2023-04-26 |
| PET Imaging of Cyclooxygenase in Multiple Sclerosis 11C-MC1, 11C-PS13, Ketoprofen - Multiple Sclerosis | Phase 2 | Terminated | National Institute of Mental Health (NIMH) | 7 | 2022-06-07 | 2024-06-27 |
| The Immunostimulatory Effects of Gentamicin Gentamicin, Placebo - Healthy Volunteers | Phase 2 | Terminated | Singapore General Hospital | 33 | 2022-05-11 | 2024-05-16 |
| Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients Canakinumab Injection - Anemia, Myelodysplastic Syndromes | Phase 2 | Terminated | University of Leipzig | 10 | 2022-04-26 | 2024-05-06 |
| A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia Delpazolid, Vancomycin, Placebo of Delpazolid - MRSA Bacteremia | Phase 2 | Terminated | LigaChem Biosciences, Inc. | 40 | 2022-04-26 | 2025-05-06 |
| A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care 101-PGC-005 ('005) + SOC, Placebo + SOC - COVID-19 | Phase 2 | Terminated | 101 Therapeutics | 3 | 2022-01-13 | 2023-02-24 |
| Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease Canakinumab, Placebo - Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 34 | 2021-10-28 | 2025-10-16 |
| Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease 40 mg Atorvastatin/day for 120 days P.O., Atorvastatin 80, Placebo - Chronic Chagas Disease | Phase 2 | Terminated | Juan D. Maya | 300 | 2021-10-12 | 2024-09-19 |
| HAT for the Treatment of Sepsis Associated With NASTI HAT, Placebo - Necrotizing Soft Tissue Infection, Sepsis | Phase 1 / Phase 2 | Terminated | Ascension Health | 10 | 2021-09-10 | 2024-07-24 |
| Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT) Standard of care without prophylaxis, Antibiotic prophylaxis - Out-Of-Hospital Cardiac Arrest, Pneumonia | Phase 2 | Terminated | David J. Gagnon | 53 | 2021-08-20 | 2025-04-17 |
| Cannabinoids in PLWHIV on Effective ART TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg), TN-C200M2 oral capsules (CBD 200 mg) - HIV Infections | Phase 2 | Terminated | McGill University Health Centre/Research Institute of the McGill University Health Centre | 10 | 2021-08-20 | 2022-06-30 |
| Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults Maraviroc + Currently used therapy, Curently used therapy for COVID-19 non-critical patients, Favipiravir + Currently used therapy - COVID-19 | Phase 2 | Terminated | Hospital General de México Dr. Eduardo Liceaga | 19 | 2021-07-13 | 2022-06-03 |
| Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems Meropenem - Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection | Phase 2 / Phase 3 | Terminated | Hospital de Clinicas de Porto Alegre | 13 | 2021-05-04 | 2022-08-03 |
| RAPA-501-Allo Therapy of COVID-19-ARDS RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo - Severe COVID-19 Disease | Phase 1 / Phase 2 | Terminated | Rapa Therapeutics LLC | 1 | 2020-12-30 | 2021-11-11 |
| INB03 for the Treatment of Pulmonary Complications From COVID-19 INB03, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Inmune Bio, Inc. | 79 | 2020-10-21 | 2026-05-19 |
Showing 20 of 108. Sign in to see all of them.
Sepsis (22) · COVID-19 (15) · Cytokine Release Syndrome (15) · Shock, Septic (14) · Coronavirus Infections (7) · Respiratory Distress Syndrome (6) · Bacteremia (5) · Critical Illness (5) · Infections (5) · Alzheimer Disease (4) · Arthritis, Rheumatoid (4) · Heart Failure (3) · Pneumonia (3) · Systemic Inflammatory Response Syndrome (3)
Pathologic Processes (108) · Pathological Conditions, Signs and Symptoms (108) · Infections (59) · Systemic Inflammatory Response Syndrome (53) · Shock (30) · Respiratory Tract Diseases (22) · Virus Diseases (22) · RNA Virus Infections (19) · Lung Diseases (18) · Coronaviridae Infections (17) · Nidovirales Infections (17) · Sepsis (17) · Respiratory Tract Infections (16) · Pneumonia, Viral (15)
Saline Solution (5) · Ascorbic Acid (4) · Sodium Chloride (4) · Standard of Care (4) · Vancomycin (4) · Daptomycin (3) · Meropenem (3) · Colchicine (2) · Etanercept (2) · Fletikumab (2) · Gentamicins (2) · Hydrocortisone (2) · Interleukin 1 Receptor Antagonist Protein (2) · Thiamine (2) · Tranexamic Acid (2)
Amgen (3) · Novo Nordisk A/S (3) · Christiana Care Health Services (2) · Federal University of São Paulo (2) · Imperial College London (2) · Inmune Bio, Inc. (2) · Johns Hopkins University (2) · National Institute of Nursing Research (NINR) (2) · Novartis Pharmaceuticals (2) · Singapore General Hospital (2) · University Hospital, Basel, Switzerland (2) · University of Athens (2) · University of Chicago (2) · University of Florida (2) · 101 Therapeutics (1)
United States (63) · Germany (12) · Canada (11) · France (9) · Spain (9) · Brazil (8) · United Kingdom (8) · Poland (6) · Australia (5) · Belgium (5) · Greece (5) · Italy (5) · Mexico (5) · Switzerland (5) · Czechia (4)
Aaron R Ritter, MD (1) · Adham Mohamed, PharmD (1) · Ajoy C Karikkineth, M.D. (1) · Anand Kumar, MD (1) · Anastasia Kotanidou, MD, PHD, Professor (1) · Anastasia Kotanidou, MD, PhD (1) · Anders Kjellberg, MD (1) · Ann Nguyen, MD (1) · Anne Sophie Kubasch, Dr. (1) · Antonio Cubillo, MD (1) · Axel R. Heller, MD (1) · Beth Gottlieb, MD (1) · Betty Diamond, MD (1)
PMID 10722036, PMID 1138591, PMID 11502226, PMID 12454520, PMID 12545007, PMID 12700374, PMID 1607900, PMID 16570523, PMID 18164921, PMID 18353115, PMID 19234342, PMID 20332511, PMID 20459801, PMID 20497755, PMID 20646908, PMID 20844049, PMID 21864392, PMID 22269279, PMID 227054, PMID 23000649, PMID 23525934, PMID 23549582, PMID 24484547, PMID 24794878, PMID 24838355, PMID 24943129, PMID 25466837, PMID 26771781, PMID 26903338, PMID 27162802, PMID 27695824, PMID 27940189, PMID 28098591, PMID 28523582, PMID 28732314, PMID 29247809, PMID 29325753, PMID 29388815, PMID 29555789, PMID 29859132, PMID 30271882, PMID 30659041, PMID 31220256, PMID 31577035, PMID 33397449, PMID 33831327, PMID 34226219, PMID 34473343, PMID 34504196, PMID 34755269
2014 (2), 1UG3DE030401-01 (1), 2018 (1), 2019 (1), K23AG052633 (1), K23HL096054 (1), P20GM139745 (1), P30CA016672 (1), UL1TR001079 (1)